Digital App Study to Improve Long-Term Aeroallergen Immunotherapy Adherence for Allergic Rhinitis Patients

What this Trial Is About

Researchers are evaluating a new digital tool to improve adherence to aeroallergen immunotherapy AIT in patients with allergic rhinitis, with or without asthma. AIT is known to help control symptoms and induce lasting immune changes, but requires at least 3 years of treatment involving daily sublingual doses or injections every 4 to 6 weeks. Despite its benefits, many patients struggle to continue treatment due to factors like cost, lack of information, and side effects, leading to low adherence rates in real life. The study compares two groups one using an active adherence-booster mobile app that sends educational messages and reminders to support patients and another using an inactive version that only collects patient feedback without intervention messages. Both groups will download the app, which also serves as an electronic case report form. The trial is randomized and will last for 3 years to assess treatment persistence. Participants will be monitored throughout the 3-year period to track how many maintain their immunotherapy. The study collects data on adherence, reasons for stopping treatment, and compares persistence at 1, 2, and 3 years between groups. Patient feedback via the app will also be gathered. The primary outcome is the proportion of patients who complete 3 years of therapy, with ongoing evaluations and data collection during the trial.

Evaluation of a Digital Tool to Improve Aeroallergen Immunotherapy Adherence. NavigAITme Project